At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
GA101 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II Study of Ibrutinib in Combination With GA101 - Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients Over 65 Years of Age or With Comorbidities That Preclude the Use of Chemotherapy Based Treatment
In Brief
A Phase 2 clinical trial evaluating GA101 and Ibrutinib for Chronic Lymphocytic Leukemia. Completed, enrolled 32 participants across 1 site.
Detailed Summary
The purpose of the study is to determine whether ibrutinib in combination with GA101 - Obinutuzumab might be useful for the treatment of CLL. This study will evaluate if ibrutinib in combination with GA101 - Obinutuzumab can reduce the amount of cancerous cells in body.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia
CountriesUnited States
CollaboratorsPharmacyclics LLC.
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartAug 2015
Primary CompletionApr 2022
TodayJul 2026
First PostedDec 12, 2014
Enrollment StartAug 26, 2015
Primary CompletionApr 18, 2022
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 11.6 years ago
Interventions
GA101drug
Ibrutinibdrug